Physician profile
Steve C Lee
NPI 1619099488
$1,683.61
in general payments reported to CMS, 2019-2025
20 companies · $70.13 in 2025
The $70.13 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2022: $275 · 2023: $522 · 2024: $708 · 2025: $70.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,300.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $397.80 | 2023-2024 | Qelbree, Qelbree |
| Corium, LLC | $227.91 | 2022-2024 | Azstarys |
| Abbvie INC. | $157.02 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.74 | 2022-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $106.65 | 2021-2023 | Trintellix |
| Lundbeck LLC | $97.21 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $96.29 | 2023-2024 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $93.61 | 2022-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $90.18 | 2023-2024 | Auvelity |
| Alkermes, INC. | $43.40 | 2024-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $42.51 | 2022-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $40.58 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $36.62 | 2021 | |
| Avion Pharmaceuticals | $24.23 | 2024 | Methylphenidate Hydrochloride |
| Collegium Pharmaceutical, INC. | $24.21 | 2025 | Jornay Pm |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $22.68 | 2021 | |
| Idorsia Pharmaceuticals US INC | $22.61 | 2023 | Quviviq |
| Tris Pharma INC | $19.45 | 2023 | Dyanavel Xr |
| Noven Therapeutics, LLC | $16.40 | 2024 | Xelstrym |
| Sunovion Pharmaceuticals INC. | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.